Document is current
Any future updates will be listed below
-
Authors
Itagaki, Mitsuhiro https://orcid.org/0009-0004-7549-4911
Kuwazawa, Hiroshi
Sasaki, Shun
Matsuura, Moe
Tanaka, Yudai
Obara, Naoshi https://orcid.org/0000-0001-6563-3093
-
Funding
Funding for this research was provided by:
Kyowa Kirin Co., Ltd.
- License Information
-
More Information
Article History
Received: 25 March 2026
Accepted: 4 May 2026
First Online: 30 May 2026
Declarations
:
: The protocol was reviewed and approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Following approval by the director of each medical institution, the study was conducted in compliance with the Declaration of Helsinki and the Japanese Ministerial Ordinance on Good Post-Marketing Study Practice (GPSP).
: Written informed consent from patients was not obtained because this requirement is waived under the GPSP ordinance. All medical institutions using romiplostim to treat patients with refractory AA were informed of the study protocol and provided written consent to publish anonymized results.
: Itagaki M received honoraria from Kyowa Kirin Co., Ltd., Alexion Pharma GK, and Janssen Pharmaceutical K.K., and consulting fees for the present manuscript from Kyowa Kirin Co., Ltd. Kuwazawa H, Sasaki S, Matsuura M, and Tanaka Y are employees of Kyowa Kirin Co., Ltd. Obara N received honoraria from Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Alexion Pharma GK and received commissioned research and joint research funding from Alexion Pharma GK, and consulting fees for the present manuscript from Kyowa Kirin Co., Ltd.
